Role of selegiline in combination therapy of Parkinson's disease

Publisher Website
Google Scholar
Abstract
In parkinsonian rat models, such as the 6-hydroxy dopamine (6-OHDA) model in which substantia nigra has been unilaterally destroyed with the toxin, selegiline enhances the effect of levodopa. [9-11] Nonselective MAO inhibitors had earlier been reported to cause some benefit but unacceptable adverse events in the treatment of Parkinson's disease (PD), [12,13] and therefore it was logical to test selegiline in this disease. The early findings by Birkmayer et al. [14] showed that selegiline potentiated the efficacy of levodopa in the treatment of PD patients and was well tolerated. This preliminary finding was followed by a number of trials assessing selegiline therapy in PD. The studies first concentrated on the use of selegiline in advanced PD, i.e., patients with …